Pancreatic Cancer Lawsuits Over Januvia, Byetta, and Victoza moving again. Byetta, Januvia, and Victoza lawsuits are back on track over Pancreatic Cancer claims with the recent Ninth Circuit Court of Appeals rulings. The federal appeals court reactivated more than 750 Byetta, Januvia, Janumet, and Victoza lawsuits brought by folks diagnosed…
In the federal court system, a Multidistrict Litigation (MDL) has been established to centralize Byetta, Januvia, Janumet and Victoza pancreatic cancer lawsuits filed in U.S. District Courts by the users of these diabetic drugs. There are currently at least 262 cases consolidated as part of an MDL, before U.S. District…
All Byetta, Januvia, Janumet and Victoza cancer lawsuits are consolidated and centralized as part of an MDL, or Multidistrict Litigation. These product liability cases involve pancreatic cancer after the use of Byetta, Januvia, Janumet or Victoza as part of the “Incretin Mimetics Product Liability Litigation.” The product liability cases are…
The U.S. Judicial Panel on Multidistrict Litigation (JPML) has agreed to consolidate all Byetta, Januvia, Janumet and Victoza cancer lawsuits, centralizing the litigation as part of an MDL, or Multidistrict Litigation. The JPML issued a Transfer Order on August 26, and these product liability cases involve pancreatic cancer after the…
According to the FDA, there is no scientific evidence to confirm that a group of type 2 diabetes drugs called GLP-1 inhibitors is linked to pancreatic cancer. The FDA decision comes on the heels of the European Medicines Agency, which stated that they have been unable to confirm an increased…
The National Institutes of Health held a workshop, addressing the risks associated with the newer diabetic drugs. These medications, known as Incretic Mimetics are coming under fire for alleged increased risk of pancreatic cancer. Merck & Co., Novo Nordisk A/S and others, the manufacturers of these drugs may be asked…